FOLLOW US

Michelle Grant, a partner in Dorsey & Whitney LLP's health litigation practice, underscores the urgency for clearer regulations amid the persistent disagreements about whether the proposed rules provide the needed clarity.

Threats of Legal Battles Loom

Amidst the chaos, threats of impending legal battles loom ominously. Industry groups, including ERIC, warn of potential legal action if the regulations are finalized without significant changes.

For instance, ERIC lambastes the agencies' focus on specific treatments as a regulatory overreach. They demand the agencies to reconsider their approach, alleging that these proposals essentially rewrite the MHPAEA statute.

 A Fight for Interpretation

The Association for Behavioral Health and Wellness, representing payers of behavioral health care, highlights issues related to the Administrative Procedure Act and cautions against arbitrary and capricious enforcement activity by the DOL, as well as potential violations of the APA.

A top House of Representatives GOP committee leader fiercely criticizes the Biden administration proposal, emphasizing that it exceeds the statutory authority of the tri-agencies.

Network Adequacy Dilemma

Another contentious battlefield emerges in the form of network adequacy. While patient advocates champion regulations to ensure network adequacy, many industry groups vehemently oppose them.

Patient advocates hail the safe harbor on network composition as a "strong requirement." However, the industry contends that such regulations could impact their ability to deny coverage and generate profits, although it's a lifeline for ERISA plan participants in dire need of essential care.

Theme In Parity Rule Comments : A Fight for Equity

In yet another twist in the saga, patient and provider advocates warn against exceptions in the rules, concerned that they could undermine the overarching objective of the new rules. These exceptions are intended to ensure that "benefit structures that apply limitations reflecting independent professional medical or clinical standards or guard against indicators of fraud, waste, and abuse" continue to be permitted.

Industry groups join the fray, calling for more specificity on the exceptions in any final rule. However, the debate remains fierce and unpredictable.

As the dust settles, the future of these proposed federal health plan regulations remains shrouded in uncertainty. The battle lines have been drawn, and the war for clarity, fairness, and compliance rages on.